Our business model

Our business model is built on partnering. Through partnerships and collaborations we can leverage our core R&D competences, expand our activities and optimize the value in our pipeline while retaining a balanced risk-reward approach. This is why we are ZealAND patients; ZealAND big pharma and biotech companies; ZealAND medical experts and care givers; and ZealAND academia. 

The starting place for our business is world-leading expertise in the field of peptide medicines 

Zealand has a fundamentally strong basis for its business activities founded on its world-
leading competences and expertise in the field of peptide drug design and development. This is evident from the number of peptides synthesized since the company’s inception 15 years ago (approximately 5,900 peptides) as well as by the approx. 800 active patents on Zealand peptide compounds, approx. 250 of which have been issued, and the nine therapeutic candidates that we have taken into clinical development.

Peptide based medicines – A growing market

Peptides have several advantages as medicines. They play important roles in regulating human physiologic functions. Peptides have a high biologic specificity and selectivity, physiological medicines based on peptides offers advantageous efficacy and safety profiles.

Peptide medicines have in general benefits over protein based medicines in terms of administration routes and manufacturing costs.

Peptide based medicines are a growing class with still unexplored potential in several disease areas. Currently, there are many marketed peptide products, several with blockbuster status these include Capoxone, Victoza, Sandostatin, Forteo, Zoladex.

Source: Transparency Market Research, Peptide Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012-2018

Key elements of our business model

From idea generation to commercialization of Zealand invented peptide medicines and associated health solutions, we rely on partnerships. This approach is key in meeting our overall strategic objectives. Our business model helps us to optimize the scope of our activities and the value of our pipeline while retaining an agile organization focused within our core expertise area of design and development of innovative peptide based therapeutics.

The size and structure of our R&D organization ensures a dynamic and interactive development process. We believe this adds optimal speed to the transition of novel peptide therapeutics from preclinical to clinical development.

The Zealand 
business model

Zealand believes that inventing and developing revolutionary health solutions requires a thorough understanding of patients and their needs as well as strong science and IP protection. We therefore interact with relevant stakeholders, including patient organizations and caregivers throughout the invention and development of a new medicine.

We have a comprehensive toolbox of peptide technologies in house which we can apply to novel peptide therapeutics. We do, however, acknowledge that many new opportunities in terms of new peptide design and formulary techniques reside outside our company. This is why we engage in collaborations with biotech companies and academia in the pre-clinical phase to ensure access to the newest techniques. The current collaboration with D.E. Shaw research is an example of our approach to leveraging the expertise of others.Zealand believes that inventing and developing revolutionary health solutions requires a thorough understanding of patients and their needs as well as strong science and IP protection. We therefore interact with relevant stakeholders, including patient organizations and caregivers throughout the invention and development of a new medicine.

We have in-house capabilities to take new peptide drug candidates in selected indications from idea phase to clinical Proof-of-Concept. For such proprietary clinical programs, however, study activities are still conducted in collaboration with leading hospital, clinical centers and via Contract Research Organizations helping us to leverage our work. This approach is essential also, to establish strong and valuable contacts at medical centers and retain a network of relevant medical key opinion leaders. An example is the Phase II clinical study we have ongoing with danegaptide, which is conducted in collaboration with Rigshospitalet, one of the world’s leading cardiac centers.

As a partnering company, Zealand intends to stay focused on invention and early development of new health solutions, with a partner eventually being responsible for the later stage development as well as commercialization.

Zealand’s integrated approach to peptide R&D

We believe that an integrated approach is essential in advancing programs at a high speed and with the lowest risk possible, and we take advantage of being an agile and flexible organization with focus on R&D activities. When an idea matures into a project, activities to find the best lead candidate are initiated. This is an iterative process where all disciplines in the company continuously provide input to allow for the most valuable assets to be advanced into the clinic.